CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR), the late-stage bio-scientific research and medical device company for early detection and treatment of reproductive-tract cancers, reports a loss of $ .03 per share for 2006 compared to a loss per share of $.04 per share for 2005. Net sales were $94,000 in 2006 compared to $117,000 in 2005. Cash balances at the end of 2006 were $874,000 vs. zero for 2005.
